Marzia Palma

7PUBLICATIONS
28CO-AUTHORS
Predictive and prognostic markersHaematological tumoursCancer therapy (excl. chemotherapy and radiation therapy)Tumour immunologyApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (7)

|Jun 27, 2026
Baseline plasma-informed circulating tumor DNA analyses comparing multiplex digital PCR and NGS for longitudinal monitoring in Hodgkin lymphoma.

|Dec 26, 2025
T-cell immunomodulation occurs with different time kinetics during acalabrutinib and zanubrutinib therapy in chronic lymphocytic leukaemia.

Maria L Andersson, Olina Lind, Kia Heimersson

|Jul 18, 2022
Temporary cessation of ibrutinib results in reduced grade 3-4 infections and durable remissions-Interim analysis of an on-off-repeat Phase 1b/2 study in patients with chronic lymphocytic leukemia.

Jeanette Lundin, Tom A Mulder, Magdalena Kättström

|Jan 25, 2022
Limited, But Not Eliminated, Excess Long-Term Morbidity in Stage I-IIA Hodgkin Lymphoma Treated With Doxorubicin, Bleomycin, Vinblastine, and Dacarbazine and Limited-Field Radiotherapy.

Ingemar Lagerlöf, Helena Fohlin, Gunilla Enblad

|Sep 26, 2021
Covid-19 in patients with chronic lymphocytic leukemia: clinical outcome and B- and T-cell immunity during 13 months in consecutive patients.

Lisa Blixt, Gordana Bogdanovic, Marcus Buggert

|Aug 21, 2018
Ibrutinib induces rapid down-regulation of inflammatory markers and altered transcription of chronic lymphocytic leukaemia-related genes in blood and lymph nodes.

Marzia Palma, Aleksandra Krstic, Lucia Peña Perez

Pageof 2

Frequent Collaborators

3 joint publications

Lotta Hansson

3 joint publications

Tom A Mulder

3 joint publications

Anders Österborg

2 joint publications

C I Edvard Smith